Horsepox vaccine to prevent smallpox infection: ‘A safer vaccine to protect against smallpox’
Tonix Pharmaceuticals Holding Corp. (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, working with researchers from the University of Alberta, a leading Canadian research university, today announced the successful synthesis of a potential smallpox-preventing vaccine. This vaccine candidate, TNX-801, is a live form of horsepox virus (HPXV) that has been demonstrated to have protective vaccine activity in mice.
Image/qimono
“Presently, the safety concern of existing smallpox-preventing vaccines outweigh the potential benefit to provide immunization of first responders or the general public. By developing TNX-801 as a horsepox vaccine to prevent smallpox infection, we hope to have a safer vaccine to protect against smallpox than is currently available,” stated Seth Lederman, M.D., president and chief executive officer of Tonix. “Vaccines are a critical component of the infrastructure of global public health. Vaccination protects those who are vaccinated and also those who are not vaccinated, by decreasing the risk of contagion.”
“Our goal is to improve on current methods that protect the public from possible viral outbreaks,” said Professor David Evans, Ph.D., FCAHS, Professor and Vice-Dean (Research), Faculty of Medicine and Dentistry at the University of Alberta, in Edmonton, Alberta, Canada, and principal investigator of the TNX-801 research project.
HPXV was synthesized by Professor Evans and Research Associate Ryan Noyce, Ph.D., at the University of Alberta, with Dr. Lederman as co-investigator of the research and co-inventor of the TNX-801 patent. Under their research and development agreement, Tonix wholly owns the synthesized HPXV virus stock and related sequences. Professor Evans and Dr. Noyce also demonstrated that HPXV has protective vaccine activity in mice, using a model of lethal vaccinia infection. Vaccine manufacturing activities have been initiated by Tonix to support further nonclinical testing of TNX-801.
Dr. Lederman stated, “Our research collaboration is dedicated to creating tools and innovative products that better protect public health.”
Horsepox, an equine disease caused by a virus and characterized by eruptions in the mouth and on the skin, is believed to be eradicated. No true HPXV outbreaks have been reported since 1976, at which time the United States Department of Agriculture obtained the viral sample used for the sequence published in 2006 that allowed the synthesis of TNX-801. In 1798, Dr. Edward Jenner, English physician and scientist, speculated that smallpox is a human version of pox diseases in animals. Jenner had a strong suspicion that his vaccine began as a pox disease in horses and went on to show that it could be used to vaccinate against smallpox. Smallpox was eradicated as a result, and no cases of naturally occurring smallpox have been reported since 1977. Jenner’s vaccine appears to have evolved considerably in the vaccinia stocks maintained in different countries around the world, since vaccinia was mostly selected for growth and production. Being able to provide safe and effective smallpox-preventing vaccines remains important and necessary for addressing and protecting public health.
Related:
- North Korea: The killing of Kim Jong-nam, VX nerve agent and other WMDs
- What is smallpox and how does the clinical presentation differ from chickenpox?
- Bioterrorism: A history, the agents and more
- Saint Louis University looking for volunteers for plague vaccine
[…] Tonix Pharmaceuticals Holding Corp. is developing the synthetic version of horsepox as a potential vaccine to prevent smallpox (variola virus) infection in humans. Seth Lederman, President and Chief Executive Office of Tonix, is co-investigator on the research and co-inventor on the designated TNX-801 patent. […]